Welcome to the TAFINLAR® + MEKINIST® on-demand webinars page.
Below you can access recordings of the latest educational webinars organised by Novartis and hosted by experts in the field of lung cancer. We’ll continue to add to the collection, so keep checking back!
Targeted therapy for BRAF+ NSCLC patients
Dr Tom Newsom-Davis, Dr Alastair Greystoke, Dr Riyaz Shah and Dr Toby Talbot come together to discuss the current testing landscape, the clinical data for Dabfrafenib+Trametinib in NSCLC and what can be learnt from the clinical experience in the melanoma setting.
Indication: Tafinlar in combination with Mekinist is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.
- Tafinlar (dabrafenib) Summary of Product Characteristics.
- Mekinist (trametinib) Summary of Product Characteristics.